A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 10
- Population
- ALL · 50 Years
- Duration
- 2008-11-01 to 2012-12-01
- Intervention
- Pegaptanib (Macugen®)
- Comparator
- Not reported
- Outcomes measured
- Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks — 54 weeks; Mean change from baseline in total size of lesion and total size of CNV at 12, 24 and 54 weeks — week 24 and 54; Changes in best corrected visual acuity (BCVA) from baseline at 54 weeks — 54 weeks; Mean change from baseline in at week 12 and 24 — week 12 and 24; Proportion of patients who gain ≥ 5, 10, 15 letters of BCVA from baseline at week 24 and 54 — week 24 and 54; Proportion of patients who lose less than 15 letters of BCVA from baseline at week 24 and 54 — week 24 and 54; Change in area of leakage at 12, 24 and 54 weeks — weeks 12, 24 and 54; Mean change in retinal thickness by OCT at center of fovea at 12, 24 and 54 weeks — weeks 12, 24 and 54
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.